Adding Obinutuzumab to Acalabrutinib-Venetoclax for CLL
July 24, 2025
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
CLL Society awarded Dr. Matthews Davids a research grant for his project Optimizing Glofitamab Combination Therapy in Richter’s Transformation.
Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.
The time-limited combination of duvelisib plus venetoclax was effective for treating relapsed / refractory CLL, but it also had significant side effects.
Hodgkin lymphoma transformation is a rare type of Richter’s transformation in which CLL / SLL turns into Hodgkin lymphoma rather than DLBCL.
Atezolizumab-venetoclax-obinutuzumab produced high remission rates, but immune-related side effects limit its usefulness as a frontline CLL therapy.
Join CLL Society and Dr. Deborah Stephens to learn how a comprehensive approach to well-being can complement your CLL care.
As more and more drugs have become available to treat CLL, doctors and patients alike want to know what is the best way to sequence these therapies.
Dr. Nicole Lamanna discusses upcoming novel therapies for CLL / SLL from the American Society for Hematology (ASH) annual meeting, a scientific conference.